Tag: arteriovenous fistula
Laminate Medical announces first implantation of VasQ AVF device
Laminate Medical has announced the first implantation of their VasQ device in the USA, performed by Ari Kramer (Spartanburg Regional Hospital, Spartanburg, USA). The...
Laminate Medical announces FDA clearance for VasQ AVF creation device
Laminate Medical Technologies has announced their flagship device, the VasQ External Vascular Support, has been cleared by the US Food and Drug Administration (FDA)...
Alucent Biomedical granted US FDA approval for clinical study
Alucent Biomedical has announced that the US Food and Drug Administration (FDA) granted an investigational device exemption (IDE) for a US clinical study of...
Study suggests Black patients more prone to dialysis graft failure
Compared to other races, African American patients are more likely to experience premature arteriovenous (AV) graft failure in the treatment of advanced kidney failure,...
VentureMed completes enrolment of Flex Vessel Prep system randomised controlled trial...
VentureMed Group recently announced that it has completed enrolment of a randomised controlled trial (RCT) titled 'Flex Vessel Prep prior to PTA for the...
Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data
The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term...
“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...
Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
Results from first-in-human study of Amplifi vein dilation system presented at...
Preliminary clinical results from a first-in-human study assessing the Amplifi vein dilation system (Artio Medical) were presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October...
Arteriovenous fistulas contribute to higher survival of haemodialysis patients with COVID-19
A new study, published online in The Journal of Vascular Access (JVA), suggests that arteriovenous fistulas (AVFs) contribute to higher survival of haemodialysis patients...
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
Arterial diameter may help to predict AVF aneurysm progression, study suggests
A recent study concludes that arterial diameter may influence arteriovenous fistula (AVF) aneurysm progression and the interval to surgical revision. “Patients with larger arterial...
VasQ device improves AVF creation in haemodialysis patients, JVA study reports
VasQ, a high haemocompatibility biosynthetic vascular device from Laminate Medical Technologies, could be protective against the haemodynamic modifications that occur during arteriovenous fistulae (AVF)...
Network meta-analysis finds DCB angioplasty “significantly superior” to plain balloon angioplasty...
A recent network meta-analysis shows that, in failing arteriovenous fistulas (AVFs) with outflow stenosis, drug-coated balloon (DCB) angioplasty is “significantly superior” to plain balloon...
Patient-specific computation model may improve AVF maturation rates
The results of a randomised controlled trial—the Shunt simulation study—show that a new patient-specific computation model accurately calculated postoperative access flow. As flow is...
Six-month IN.PACT AV Access results show superiority of DCB angioplasty
Just-published six-month results of the IN.PACT AV Access study show that drug-coated balloon (DCB) angioplasty is superior to standard angioplasty for the treatment of...
VasQ external support awarded breakthrough device designation by the FDA
The US Food and Drug Administration (FDA) has designated Laminate Medical’s VasQ external support for the creation of arteriovenous fistulas (AVF) in haemodialysis patients...
Enrolment of the VasQ external support US pivotal study now complete
Laminate Medical Technologies has announced the completion of enrolment into the VasQ external support US pivotal study. The study was conducted at 17 sites...
e-PTFE covered stent demonstrates “significantly better” target lesion primary patency compared...
The results of AVeNEW, the first level one clinical study dedicated solely to the use of a covered stent designed to treat stenosis in...
MagicTouch AVF sirolimus-coated balloon granted FDA breakthrough device designation
Concept Medical has been granted breakthrough device designation from the US Food and Drug Administration (FDA) for MagicTouch AVF, its sirolimus drug-coated balloon (DCB)...
Promising first-time data indicate human stem cell trial is safe, prompting...
A first-in-human, phase I clinical trial using stem cells to prevent venous stenosis formation in arteriovenous (AV) fistulas yields promising results. Sanjay Misra (Mayo...
Covered stent provides greater patency than angioplasty alone in AV fistulae
The Covera vascular covered stent (BD) has a superior six-month primary patency rate than standard balloon angioplasty, with an equivalent safety at 30 days,...
Latest data on Lutonix and IN.PACT drug-coated balloons in AV access...
There in an increasing physician interest in exploring the role of drug-coated balloons in arteriovenous (AV) access. At the Leipzig Interventional Course (LINC; 30...
